---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063167"
form_type: "8-K"
ticker: null
cik: "0001463361"
company_name: "Unity Biotechnology, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T17:05:17.992613+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Unity Biotech lays off all employees, explores strategic alternatives after Phase 2b miss

## Summary
- Company reducing entire workforce; expects $3.7M in severance and related cash costs; completion by May 15, 2025.
- CEO Anirvan Ghosh, CFO Lynne Sullivan, and Chief Legal Officer Alexander Nguyen will terminate employment May 15, transition to advisory consulting roles.
- Phase 2b ASPIRE study of UBX1325 in DME showed non-inferiority to aflibercept at week 36 but missed primary endpoint at average of weeks 20 and 24.
- Strategic alternatives include sale, license, monetization, merger, or wind-down of the company; no assurance of any transaction.
- Cash and equivalents $16.9M as of March 31, 2025; company reducing operational cash burn.

## SEC filing metadata
- accession: 0000950170-25-063167
- form_type: 8-K
- cik: 0001463361
- company_name: Unity Biotechnology, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.05, 8.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/ubx-20250502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063167
- JSON: https://secwatch.observer/filing/0000950170-25-063167.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063167.txt

## Key facts
- Executive change
  Anirvan Ghosh departed as Chief Executive Officer at Unity Biotechnology, Inc..
  - Action: terminated employment
  - Role: Chief Executive Officer
  source text: each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm
- Executive change
  Lynne Sullivan departed as Chief Financial Officer and Head of Corporate Development at Unity Biotechnology, Inc..
  - Action: terminated employment
  - Role: Chief Financial Officer and Head of Corporate Development
  source text: each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm
- Executive change
  Alexander Nguyen departed as Chief Legal Officer and Head of Operations at Unity Biotechnology, Inc..
  - Action: terminated employment
  - Role: Chief Legal Officer and Head of Operations
  source text: each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm
- Restructurings & Charges
  Unity Biotechnology, Inc. announced a restructuring with charges of approximately $3.7 million (a reduction in force affecting all of its employees).
  - Type: restructuring
  - Charge: approximately $3.7 million
  - Headcount: a reduction in force affecting all of its employees
  source text: The Company estimates that it will incur aggregate cash expenses of approximately $3.7 million in connection with the reduction in force, including severance, benefits, and related termination costs, which includes fees to be paid under consulting agreements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.